What Has Been the Growth of the Anti-Asthmatics And COPD Drugs Market So Far?
The anti-asthmatics and copd drugs market has seen considerable growth due to a variety of factors.
• The market size for anti-asthmatics and COPD drugs has seen substantial growth in recent years, with predictions to increase from $80.82 billion in 2024 to $86.11 billion in 2025, presenting a Compound Annual Growth Rate (CAGR) of 6.6%.
Factors contributing to the growth during the historic period include the higher occurrence of respiratory ailments, a rise in tobacco smoking, the impact of global warming, an aging population, the emergence of new markets, innovative techniques for drug discovery, and increased spending in healthcare.
What Is the Forecasted Market Size and Growth Rate for The Anti-Asthmatics And COPD Drugs Market?
The anti-asthmatics and copd drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for anti-asthmatics and COPD drugs is projected to experience robust growth over the next few years, reaching a value of $107.01 billion in 2029. This represents a compound annual growth rate (CAGR) of 5.6%.
Several factors are driving the marked growth in this timeframe. These include the rising popularity of e-cigarettes/vaping, increasing obesity rates, advancements in technology, a substantial undiagnosed population, leveraging these drugs for COVID-19 treatment, and a growing intake of fats. Predicted trends for this period encompass the development of probiotic drug treatments for asthma and anti-il-5 medications to broaden business offerings. Additionally, the launching of innovative products will help solidify market standing amid heavy competition. Other strategies will involve heavier investments in bioelectric medicine development, fostering collaboration initiatives, offering personalized therapy, creating combination drugs for heightened efficacy, and developing biologics to take advantage of increasing demand.
Which Drivers Are Accelerating Growth In The Anti-Asthmatics And COPD Drugs Market?
The anti-asthmatics and COPD drugs market is significantly influenced by alterable risk factors such as smoking, lack of physical activity, and unhealthy dietary practices. Although there is a global decline in the prevalence of smoking, developing nations like China, India, Indonesia, and Nigeria among others are experiencing an increase in smoking rates. For example, by 2025, Indonesia is projected to have a rise of 24 million smokers and Nigeria an increase of 7 million. Over 40% of the worldwide consumption of cigarettes is concentrated in China. The consumption of fats, especially saturated fatty acids, a recognized risk factor for Asthma and COPD, is more prevalent in wealthy nations like the USA and Europe. As per the World Health Organisation, in developed nations, fats contribute to over 35% of the total energy requirement, in contrast to less than 20% in low-income nations, and under 25% in lower-middle-income nations.
What Key Areas Define The Segmentation Of The Global Anti-Asthmatics And COPD Drugs Market?
The anti-asthmatics and COPD drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Pre-Book The Anti-Asthmatics And COPD Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Anti-Asthmatics And COPD Drugs Market?
Leading companies in the anti-asthmatics and COPD drugs market are pioneering new products like the fixed-dose combination (FDC) drug, Indacaterol plus Mometasone, to enhance their market profitability. Utilizing the Breezhaler device, Indacaterol plus Mometasone is a once-per-day FDC medication intended for continuous asthma management in patients. For instance, Glenmark Pharmaceuticals, a US-based firm, introduced a unique fixed-dose combination drug, Indacaterol plus Mometasone, for treating patients with unmanageable asthma in India in June 2022. This medication, known as Indamet, is offered in three variants, each containing a consistent 150 mcg dose of Indacaterol and differing doses of Mometasone, available in 80 mcg, 160 mcg, and 320 mcg strengths.
Who Are the Key Players in the Anti-Asthmatics And COPD Drugs Market?
Major companies operating in the anti-asthmatics and COPD drugs market include:
• GlaxoSmithKline plc
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Sanofi S.A.
• Chiesi Farmaceutici S.p.A.
• Teva Pharmaceutical Industries Limited
• Merck & Co. Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• China National Pharmaceutical Group Co. Ltd. (Sinopharm)
• Shanghai Acebright Pharmaceuticals Group Co. Ltd.
• Jiangsu Hengrui Medicine Co. Ltd
• Hanmi Pharmaceutical
• Cipla Limited
• Aurobindo Pharma Limited
• KYORIN Holdings Inc.
• Nichi-Iko Pharmaceutical Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Daewoong Pharmaceutical Co. Ltd
• Shanghai Anovent Pharma
• China Meheco Group Co. Ltd.
• Lupin Limited
• ASGEN Pharmaceutical Co. Ltd
• Abbott Laboratories
• Pfizer
• Vectura Group
• Bristol Myers Squibb
• Apotex Inc.
• EMS Pharma
• Hypermarcas
• Ache
• Eurofarma
• Bayer
• Biolab Farmaceuticad
• Cristalia
• Libbs
• Julphar
• Neopharma
• Adcock Ingram
• Aspen Nigeria
What Is The Most Dominant Region In The Anti-Asthmatics And COPD Drugs Market?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
